Shire in a spin over Vyvanse.
Investors Chronicle - magazine and web content, February, 2008
Shires shares have plummeted after high-profile brokers downgrade them on concerns customers aren't switching to its new ADHD drug, Vyvanse Richard Hemming
First it was US-based broker Sanford C. Bernstein, then it was Goldman Sachs. Shire's share price has fallen off a cliff after the high profile broker downgrades, declining by over 20 per cent in the past 20 trading days.
There is increasing nervousness that Shire is not managing to switch as many customers as it had hoped for into its new attention deficit hyperactivity disorder (ADHD) treatment, Vyvanse, prior to the advent of Adderall XR generics coming on to the market in April 2009. Sales of Adderall XR are expected to comprise about 40 per cent of Shire's GBP2.4bn total sales in 2007. So...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
